Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco Ltd. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Invesco Ltd. trades at $28.79 (market cap $12.85B). The key difference: Invesco Ltd. is far larger — about 6.5× Amylx Pharmaceuticals Inc's market cap, and Invesco Ltd. pays a 2.97% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | IVZ | |
|---|---|---|
Market Cap | $1.98B | $12.85B |
Sector | Health | Financials |
52-Week High | $18.70 | $29.44 |
52-Week Low | $7.64 | $16.74 |
Enterprise Value | $1.70B | $23.09B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
IVZ trades at $28.98, up 1.29% today, with a bullish technical signal and analyst consensus price target of $29.79. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, while the company reported a net loss of $281.70 million in 2025. Positive cash flow from operations of $1.53 billion and a recent dividend payment of $0.22 per share highlight financial stability amid profitability challenges.
The outlook for IVZ is cautiously optimistic, supported by strong analyst buy ratings and improving assets under management, but weighed down by negative net income margins and competitive pressures in asset management. Key risks include execution on profitability and market volatility affecting AUM growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
